ITRM
Iterum Therapeutics plc
Set alert
0.03 USD 0.00 0.00%
0.0283 Day range 0.047
0.808 52-week range 3.02
- YTD
- -91.04%
- 1 year
- -96.91%
- Open
- 0.0415
- Prev close
- 0.03
- Mkt cap
- 48.98M
- Vol
- 49.30M
- Avg vol
- 2.88M
- EPS
- -1.76
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0283
- High
- 0.047
- Forward P/E
- -2.70
- Beta
- 2.25
- Short ratio
- 0.46
- Inst. own
- 8.99%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.63
- 200-d avg
- 1.40
- 1y target
- 7.50
Key statistics
- Market cap
- 48.98M
- Enterprise value
- 40.78M
- Trailing P/E
- 0.00
- Forward P/E
- -2.70
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -1.76
- Beta
- 2.25
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -28.46M
- Total cash
- 11.72M
- Total debt
- 21.62M
- Return on equity
- 0.00%
- Shares outstanding
- 27.52M
- Short % of float
- 11.53%
- 50-day average
- 1.63
- 200-day average
- 1.40
Analyst view
Consensus: none
Price target (mean) 7.50 +24900.0% upside
Now 0.03
- Target (low)
- 5.00
- Target (mean)
- 7.50
- Target (high)
- 10.00
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy2
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.24.
Financials — quick view
ITRM Revenue — quarterly 390.00K
ITRM Net income — quarterly -8.98M
ITRM EPS — quarterly -0.20
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.23 | -0.30 | -0.07 | -30.43% |
| Aug 14, 2024 | Jun 1, 2024 | -0.52 | -0.30 | +0.22 | +42.31% |
| Aug 14, 2024 | Jun 1, 2024 | -0.52 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.57 | -0.46 | +0.11 | +19.30% |
| May 13, 2024 | Mar 1, 2024 | -0.57 | — | — | — |
| Mar 28, 2024 | Dec 1, 2023 | -1.02 | -0.94 | +0.08 | +7.84% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jun 21, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 30, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Apr 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Iterum Therapeutics plc
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Ireland
- Website
- iterumtx.com
News
- Sol-Gel Technologies (NASDAQ:SLGL) & Iterum Therapeutics (NASDAQ:ITRM) Head to Head Review
- Iterum Therapeutics (NASDAQ:ITRM) vs. Scilex (NASDAQ:SCLX) Critical Review
- Reviewing Iterum Therapeutics (NASDAQ:ITRM) and Ono Pharmaceutical (OTCMKTS:OPHLF)
- 12 Health Care Stocks Moving In Tuesday's After-Market Session
- 12 Health Care Stocks Moving In Tuesday's Intraday Session
- Gold Gains Over 1%; FactSet Research Raises FY2026 Outlook
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Dow Gains 200 Points; Bullfrog AI Shares Jump
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
Your note
Sign in to keep a note on ITRM — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHIN MARK | Director | Conversion of Exercise of derivative security | Jun 14, 2023 | 18,306 |
| DUNNE MICHAEL W | Director | Conversion of Exercise of derivative security | Aug 5, 2024 | 220,001 |
| FISHMAN COREY N | Chief Executive Officer | Conversion of Exercise of derivative security | Aug 5, 2024 | 137,062 |
| HECHT BETH P | Director | Conversion of Exercise of derivative security | Jun 14, 2023 | 18,839 |
| HUNT RONALD M | Director | Conversion of Exercise of derivative security | Aug 5, 2024 | 0 |
| MATTHEWS JUDITH M | Chief Financial Officer | Conversion of Exercise of derivative security | Mar 9, 2023 | 8,135 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Armistice Capital, LLC | 4.87% | 1,340,000 | 2.39M | Sep 29, 2024 |
| New Leaf Venture Partners, L.L.C. | 1.25% | 345,020 | 614.13K | Sep 29, 2024 |
| Apollon Financial, LLC | 0.82% | 224,750 | 400.05K | Sep 29, 2024 |
| Alpine Global Management, LLC | 0.24% | 64,833 | 115.40K | Sep 29, 2024 |
| Xtx Topco Ltd | 0.12% | 33,040 | 58.81K | Sep 29, 2024 |
| Two Sigma Securities, LLC | 0.05% | 14,947 | 26.61K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.04% | 12,370 | 22.02K | Oct 30, 2024 |